Abstracts tagged "Inflammation"

Abstract Number: 0068 • ACR Convergence 2025
Unique Fibroblast-like Synoviocyte Phenotype with Elevated MCSF Expression Induced by TLR5 Activation in Rheumatoid Arthritis
Aryan Patel¹, Osama Al Zoubi² and Shiva Shahrara³, ¹University of Illinois at Chicago, Chicago, ²University of Illinois at Chicago, Chicago, IL, ³University of Illinois, Chicago, IL
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease affecting approximately 1% of the global population, causing significant morbidity and disability. Fibroblast-like synoviocytes (FLS) are…
Abstract Number: 2585 • ACR Convergence 2025
The effect of prophylactic colchicine use on gene expression in gout
Austin Wheeler¹, Guanqi Lu², Ana Vazquez³, Jeffrey Edberg⁴, Angelo Gaffo⁵, Tate Johnson¹, Michael Duryee¹, James O'Dell¹, Jeff Newcomb¹, Michael Pillinger⁶, Robert Terkeltaub⁷, Ryan Ferguson⁸, Mary Brophy⁸, Tuhina Neogi⁹, Bryant England¹, Ted Mikuls¹, Tony Merriman¹⁰ and Richard Reynolds⁴, ¹University of Nebraska Medical Center, Omaha, NE, ²Michigan State University, East Lansing, MI, ³Michigan State University, Miami, FL, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Division of Rheumatology and Clinical Immunology, University of Alabama, Birmingham, AL, USA; Birmingham VA Medical Center, Birmingham, AL, USA, Birmingham, AL, ⁶New York University Grossman School of Medicine, New York,, NY, ⁷Retired, San Diego, CA, ⁸VA Cooperative Studies Program Coordinating Center, Boston, MA, ⁹Boston University School of Medicine, Boston, MA, ¹⁰University of Alabama at Birmingham, Homewood, AL
Background/Purpose: Colchicine is recommended for the treatment and prophylaxis of gout flares and approved for secondary prevention of ischemic cardiovascular disease (CVD). While its primary…
Abstract Number: 2091 • ACR Convergence 2025
Multiplanar MRI Quantification of Effusion-Synovitis: Reliability and Potential Investigative Utility for Inflammation-Mediated Knee Conditions
Greg Gilles¹, Dagoberto Robles², Luke Grawer³, Nathaniel H. Christiansen⁴, Karim Jayyusi³, Ali Shaikh³, Rongrong Tang⁵, Mihra S. Taljanovic³, Jeffrey Duryea⁶, Edward J. Bedrick⁵ and C. Kent Kwoh⁷, ¹University of Arizona Arthritis Center, The University of Arizona College of Medicine, Tucson, AZ, ²University of Arizona, Tucson, AZ, ³University of Arizona, Tucson, ⁴University of Arizona, Stockton, NJ, ⁵The University of Arizona Arthritis Center, University of Arizona, Tucson, ⁶Brigham and Women’s Hospital, Boston, MA, ⁷The University of Arizona Arthritis Center, University of Arizona, Tucson, AZ
Background/Purpose: Effusion-synovitis (ES) is often seen in knee osteoarthritis (KOA), and MRI-detected ES may serve as a potential imaging biomarker of disease activity, progression, and…
Abstract Number: 1799 • ACR Convergence 2025
Validating the Gouty Arthritis Alleviating Effects of Cerevisterol through Integrated In Silico, In Vitro, and In Vivo Studies
Xiao-Na Ma¹, Mei-Feng Shi¹, Qian Chen¹, Fang-Shu Zou¹, Wei Feng¹, Qing-Ping Liu¹, Chang-Song Lin¹, Nan Li², Xiao-Bao Liu¹ and Qiang Xu¹, ¹Guangzhou University of Traditional Chinese Medicine, Guangzhou, China (People's Republic), ²School of Traditional Chinese Medicine, Jinan University, Guangzhou, China (People's Republic)
Background/Purpose: Zhuling has traditionally been utilized in the treatment of gouty arthritis (GA). Although its therapeutic benefits are recognized, the molecular mechanisms underlying Zhuling's action…
Abstract Number: 1466 • ACR Convergence 2025
Impact of Bimekizumab on Spinal MRI Inflammation and Structural Lesions in Patients with Radiographic Axial Spondyloarthritis: 2-Year CANDEN Scoring Results from a Phase 3 Study and Its Open-Label Extension
Walter P. Maksymowych¹, Robert G. W. Lambert², Victoria Navarro-Compan³, Xenofon Baraliakos⁴, Jason Coarse⁵, Natasha de Peyrecave⁶ and Mikkel Ostergaard⁷, ¹Department of Medicine, University of Alberta, ⁵⁶⁸ Heritage Building, Edmonton, AB, Canada, ²University of Alberta, Department of Radiology & Diagnostic Imaging, Edmonton, AB, Canada, ³Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁵UCB, Morrisville, NC, ⁶UCB, Brussels, Belgium, ⁷Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, and Copenhagen Center for Arthritis Research, Center for Rheumatology, Rigshospitalet, Glostrup, Denmark
Background/Purpose: Spinal inflammation and structural progression are key features of radiographic axial spondyloarthritis (r-axSpA).1 Canada-Denmark (CANDEN) scoring enables anatomical-based assessments of MRI inflammatory and structural…
Abstract Number: 1127 • ACR Convergence 2025
The Pathogenetic Role of Calcium Pyrophosphate and Basic Calcium Phosphate Crystals in Osteoarthritis: Associations with Synovial Fluid Cytokines and Clinical Indices
Francesca Oliviero¹, Chiara Baggio², Amelia Damasco², Federico Zorzi³, Mariagrazia Lorenzin², Giacomo Cozzi² and Roberta Ramonda⁴, ¹Rheumatology Unit, Department od Medicine - DIMED, University of Padova, Padova, Veneto, Italy, ²Rheumatology Unit, Department of Medicine - DIMED, University of Padova, Padova, Veneto, Italy, ³Center for Analysis and Certification Services (CEASC), University of Padova, Padova, Veneto, Italy, ⁴Rheumatology Unit-DIMED-University of Padova ITALY, Padova, Padua, Italy
Background/Purpose: Calcium pyrophosphate (CPP) and basic calcium phosphate (BCP) crystals are frequent features of synovial fluid (SF) in patients with osteoarthritis (OA). Although these crystals…
Abstract Number: 0920 • ACR Convergence 2025
Functional Characterization of NEMO-NDAS Causing Variants in Patients’ PBMCs and in Wildtype and Mutant U937 Cells
Elizabeth Morgan¹, Bin Lin², Sara alehashemi¹, Adriana de Jesus¹, Keith Kauffman³, Christopher Friend¹, Farzana Bhuyan¹, Kader Gedik¹, Kat Uss¹, Lauren Krausfeldt⁴, Jason Brenchley⁵, Zoran Gucev⁶, Kathryn Cook⁷, Vafa Mammadova⁸, Gulnara Nasrullayeva⁸, Mariana Correia Marques⁹, Abigail Bosk¹⁰, Brian Nolan¹¹, Scott Canna¹², Maude Tusseau¹³, Andrea Bohrer¹⁴, Katrin Mayer-Barber¹⁵, Timothy Moran¹⁶, Andrew Oler⁴, Daniel Barber³ and Raphaela Goldbach-Mansky¹, ¹Translational Autoinflammatory Diseases Section (TADS), Laboratory of Clinical Immunology and Microbiology (LCIM), NIAID, NIH, Bethesda, MD, ²NIH, Bethesda, MD, ³T-Lymphocyte Biology Section, Laboratory of Parasitic Diseases, NIAID, NIH, Bethesda, MD, ⁴Bioinformatics and Computational Biosciences Branch, Office of Cyber Infrastructure and Computational Biology, NIAID, NIH, Bethesda, MD, ⁵Barrier Immunity Section, Laboratory of Viral Diseases, NIAID, NIH, Bethesda, MD, ⁶University Children's Hospital, Medical Faculty Skopje, Skopje, Macedonia, ⁷Akron Children’s Hospital, Akron, OH, ⁸Azerbaijan Medical University, Baku, Azerbaijan, ⁹Translational Genetics and Genomics Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ¹⁰Children’s National Hospital, Washington DC, ¹¹Lurie Children’s Hospital, Chicago, ¹²Children's Hospital of Philadelphia, Philadelphia, PA, ¹³Hôpital Femme-Mère-Enfant, Bron, France, ¹⁴Inflammation and Innate Immunity Unit, Laboratory of Clinical Immunology and Microbiology (LCIM), NIAID, NIH, Bethesda, MD, ¹⁵Inflammation and Innate Immunity Unit, Laboratory of Clinical Immunology and Microbiology (LCIM), Bethesda, MD, ¹⁶University of North Carolina School of Medicine, Chapel Hill, NC
Background/Purpose: NEMO-deleted 5 autoinflammatory syndrome (NEMO-NDAS) is an inflammatory disease caused by mosaic splice-site variants that lead to exon 5 skipping in IKBKG, encoding NEMO.…
Abstract Number: 0489 • ACR Convergence 2025
Efficacy and safety profile of JAK inhibitors in current practice in rheumatoid arthritis
Omar Al Tabaa¹, Salomé Abdellaoui¹, Sophie Hecquet¹, Marion Thomas², Sandrine Carves¹, Alice Combier¹, Olivier Fogel³, Yannick Allanore⁴ and Jérôme Avouac⁵, ¹Rheumatology department, Cochin Hospital, Paris, France, ²APHP, Paris, France, ³AP-HP, Paris, France, ⁴Université Paris Cité, Paris, France, ⁵Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France
Background/Purpose: JAKi have been used in rheumatoid arthritis in current practice for several years now, with the progressive arrival on the market of 4 molecules.…
Abstract Number: 0233 • ACR Convergence 2025
Differential Effects of GLP-1 Receptor Agonists versus SGLT2 Inhibitors on Hypoglycemia and Infection Risk in Diabetic Patients with Inflammatory Arthritis
Godbless Ajenaghughrure¹, Sila Mateo Faxas², Gurjot Singh³, Nirys Mateo Faxas⁴, Kim Nguyen³, Nicole Tejeda⁵ and Kimberly Ramirez Bonetti⁶, ¹Trihealth Good Samaritan Hospital, Cincinnati, OH, ²Good Samaritan Hospital, Cincinnati, OH, ³Trihealth Good Samaritan Hospital, Cincinnati, ⁴Independent Author, Santo Domingo, Dominican Republic, ⁵Independent Author, Cincinnati, ⁶Independent Author, cincinnati, OH
Background/Purpose: While both SGLT2 inhibitors and GLP-1 receptor agonists improve glycemic control in type 2 diabetes (T2D), their safety profiles, particularly regarding hypoglycemia and infection…
Abstract Number: 0066 • ACR Convergence 2025
RA-required synovial tissue-resident monocyte lineage cells are comprised of three distinct subpopulations.
Yidan Wang¹, Samuel Dowling², Jessica Maciuch², Vanessa Manada De Lobos², Meghan Mayer², Kainat Mian¹, Tyler Therron³, Hadijat Makinde¹, Carla Marie Cuda¹, Deborah Rachelle Winter⁴ and Harris R Perlman¹, ¹Northwestern University, Chicago, IL, ²Northwestern University, Chicago, ³Northwestern Feinberg School of Medicine, Chicago, IL, ⁴Northwestern University, Skokie, IL
Background/Purpose: Tissue-resident monocyte-lineage cell (TRMC) are an extravascular population distinct from circulating monocytes and synovial macrophages and are critical for the development of inflammatory arthritis.…
Abstract Number: 2527 • ACR Convergence 2025
Safety Profile and Impaired Humoral Response to the Recombinant Herpes Zoster Vaccine in Behçet’s Syndrome Patients under Immunosuppression: a Prospective, Randomized, Placebo-Controlled Trial
Eduardo Borba¹, Caio Carvalho², Nadia E Aikawa³, Ana C Medeiros-Ribeiro², Sandra G Pasoto², Carla Saad⁴, Henrique Giardini⁵, Thiago Freitas⁵, Rafael Cordeiro⁶, Eloisa Bonfa¹ and Clovis Artur Silva⁷, ¹Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ³Pediatric Rheumatology Unit, Instituto da Criança e do Adolescente, Hospital das Clinicas HCFMUSP, Sao Paulo, Brazil., Sao Paulo, Sao Paulo, Brazil, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Sao Paulo, Brazil, ⁵Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Brazil, ⁶Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Sao Paulo, Brazil, ⁷University of São Paulo, São Paulo, São Paulo, Brazil
Background/Purpose: Although rare, new-onset Behçet’s syndrome (BS) and disease flares have been reported following vaccination. In this context, the recommendation of the Recombinant Herpes Zoster…
Abstract Number: 2085 • ACR Convergence 2025
Estimating the Association between Effusion-synovitis and Knee Pain in a Subset of Participants with Radiographic Knee Osteoarthritis: Data from the Osteoarthritis Initiative (OAI)
Dagoberto Robles¹, Greg Gilles², Nathaniel H. Christiansen³, Luke Grawer⁴, Karim Jayyusi⁴, Ali Shaikh⁴, Rongrong Tang⁵, Mihra S. Taljanovic⁴, Jeffrey Duryea⁶, Edward J. Bedrick⁵ and C. Kent Kwoh⁷, ¹University of Arizona, Tucson, AZ, ²University of Arizona Arthritis Center, The University of Arizona College of Medicine, Tucson, AZ, ³University of Arizona, Stockton, NJ, ⁴University of Arizona, Tucson, ⁵The University of Arizona Arthritis Center, University of Arizona, Tucson, ⁶Brigham and Women’s Hospital, Boston, MA, ⁷The University of Arizona Arthritis Center, University of Arizona, Tucson, AZ
Background/Purpose: Even though knee pain is ubiquitous in knee osteoarthritis (KOA) patients, currently there are limited treatment options which are only minimally or moderately efficacious…
Abstract Number: 1785 • ACR Convergence 2025
Soluble CD14 Amplifies Chondrocyte Inflammatory Responses to Lipopolysaccharide and Is Targetable by Anti-CD14 Therapy
Anna Rapp¹, Kate Sharp¹, Baofeng Hu² and Carla Scanzello¹, ¹University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Wynnewood, PA
Background/Purpose: Osteoarthritis (OA) is characterized by a pro-inflammatory joint microenvironment, including elevated levels of endogenous pattern recognition receptor ligands in synovial fluid. Notably, both lipopolysaccharide…
Abstract Number: 1458 • ACR Convergence 2025
Clinical Efficacy of Bimekizumab Treatment up to 2 Years Across Patients with Psoriatic Arthritis and Varying Baseline Joint Involvement: Results from a Post Hoc Analysis of Two Pooled Phase 3 Studies
Philip J. Mease¹, Laure Gossec², Hideto Kameda³, David Nicholls⁴, Proton Rahman⁵, Barbara Ink⁶, Rajan Bajracharya⁶, Patrick Healy⁷ and Laura Coates⁸, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France, ³Department of Internal Medicine, Toho University, Tokyo, Japan, ⁴Clinical Trials Unit, University of the Sunshine Coast, Queensland, Australia, ⁵Division of Rheumatology, Craig L. Dobbin Genetics Research Centre, Discipline of Medicine, Memorial University of Newfoundland, St. John's, Canada, ⁶UCB, Slough, England, United Kingdom, ⁷UCB, Morrisville, NC, ⁸Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom
Background/Purpose: Patients (pts) in PsA clinical trials often have greater joint involvement than in the clinical setting due to trial inclusion criteria,1 thus it is…
Abstract Number: 1119 • ACR Convergence 2025
Microbial activation of cytotoxic CD8⁺ T cells promotes skin immune-related adverse events in patients treated with immune checkpoint inhibitors
Shady Younis¹, Suman Acharya¹, Gayathri Swaminathan¹, Heidi Wong¹, Hannah Kim¹, Alec Eschholz¹, Subramanya Hegde², Andrew McKnight³, William Robinson⁴ and Lisa Zaba¹, ¹Stanford University, Stanford, CA, ²Sanofi US, New Jersey, MA, ³Sanofi US, Cambridge, MA, ⁴Stanford University, Palo Alto, CA
Background/Purpose: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, but their use is often limited by immune-related adverse events (irAEs), particularly in barrier tissues such…

« Previous Page
1
…
3
4
5
6
7
…
67
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].